Trump says Iran war "close to over" amid hopes for more negotiations
SMITH FALLS, Ontario & TUTTLINGEN, Germany - Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) announced Thursday the appointment of David Männer as managing director of its subsidiary Storz & Bickel, effective April 1, 2026, according to a press release statement.
Männer, a 14-year veteran of Storz & Bickel who most recently served as deputy managing director, will succeed co-founder Jürgen Bickel. Bickel, who established the company in 2001, is transitioning out of his role after 25 years of leadership.
"Storz & Bickel is the best in the world at what we do. I am thrilled to entrust its next chapter to someone I have complete confidence will carry it successfully into the future," Bickel stated.
Storz & Bickel manufactures vaporization devices and holds ISO 13485 certification for medical-grade devices. The company has received the Dr. Rudolf Eberle Prize for technical innovation.
"Jürgen has built a culture of product excellence, a discipline around standards, and a passionate team. It is on this foundation that I am excited to apply what I’ve learned and write the next chapter," Männer said.
Luc Mongeau, chief executive officer of Canopy Growth, said the company plans to deepen its presence in the U.S. and advance product innovation under Männer’s leadership. InvestingPro Tips highlight that the stock exhibits high volatility and the company is burning through cash quickly—two of 7 additional tips available to subscribers seeking deeper investment insights.
Canopy Growth operates cannabis brands including Tweed, 7ACRES, and DOJA, and provides medical cannabis services through Canada House Clinics Inc. The company holds an unconsolidated, non-controlling interest in Canopy USA, which includes ownership stakes in Acreage Holdings, Inc. and Wana Wellness, LLC.
Storz & Bickel is based in Tuttlingen, Germany.
In other recent news, Canopy Growth Corporation has successfully completed its acquisition of MTL Cannabis Corp. This acquisition involved Canopy Growth acquiring all outstanding common shares of MTL Cannabis, with MTL shareholders receiving 0.32 of a Canopy Growth share and $0.144 in cash for each MTL share held. The transaction resulted in the issuance of approximately 41.2 million shares and a cash payment of approximately C$18.5 million. Additionally, Canopy Growth issued 2,956,391 shares to certain former shareholders of Montreal Cannabis Medical, Inc., with an 18-month transfer restriction. The acquisition was overwhelmingly approved by MTL Cannabis shareholders, with 99.97% voting in favor at a special meeting. Approximately 89% of MTL shareholders participated in the vote, demonstrating strong support for the plan of arrangement. The transaction was initially announced earlier this year and was expected to close before the end of March 2026, pending final court and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.